Recent Updates
Recently added Catalysts
PFE Positive Sentiment

Pfizer Appoints Cecile Guegan as Chief Financial Officer

Tuesday, November 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Pfizer appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026. The Board unanimously selected Guegan, who has served as interim CFO since August 16, 2026. She will now lead the company’s financial operations and strategic planning efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • Cecile Guegan appointed as CFO
  • Unanimous decision by the Board of Directors
  • Cecile has experience as interim CFO
  • Strong track record in financial leadership

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+30%
120-day peak, hindsight
Typical move
1.3%
average across 15 past catalysts
Lead asset
ibuzatrelvir
Phase 3 · COVID-19 SARS-CoV-2 Infection

Full Press Release Details

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has unanimously appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026. Cecile has served as interim Chief Financial Officer since August 16, 2026, steering the company’s financial operations, execution and strategic planning. “Cecile is an exceptional finance leader who knows our company and industry deeply, and she has a proven track record of opt

Frequently Asked Questions

Who was appointed as Pfizer's CFO?

Cecile Guegan was appointed as Pfizer's Chief Financial Officer.

When will Cecile Guegan officially start as CFO?

She will officially start as CFO on November 1, 2026.

What role did Cecile Guegan hold before her appointment?

She served as the interim Chief Financial Officer since August 16, 2026.

How did the Board of Directors decide on her appointment?

The Board of Directors unanimously appointed Cecile Guegan as CFO.

ShareAdd on Google
Tags: PFE Pfizer Cecile Guegan CFO financial operations Board of Directors
Last updated: Nov 3, 2026

Biotech snapshot

Cash runway
$11699M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ibuzatrelvirPhase 3
COVID-19 SARS-CoV-2 Infection →

Catalyst track record

+30%
best trade around PFE's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for PFE.

See every catalyst's timing & PoA →